DANZITEN vs IMKELDI

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate

Possible drug interaction. DANZITEN and IMKELDI are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	DANZITEN	IMKELDI
Rating	70/100	New
Pharmacy pays	—	~$25.80 /30
Type	RX	RX
Active ingredient	NILOTINIB TARTRATE	IMATINIB MESYLATE
Manufacturer	Azurity	Shorla Oncology
Dosage forms	Tablet	Solution
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	Boxed warning	None
Treats	Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia, Gastrointestinal Stromal Tumors	Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

danziten imkeldi

Rating

70/100

New

Pharmacy pays

—

~$25.80 /30

Type

Active ingredient

NILOTINIB TARTRATE

IMATINIB MESYLATE

Manufacturer

Azurity

Shorla Oncology

Dosage forms

Tablet

Solution

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia, Gastrointestinal Stromal Tumors

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Frequently asked questions

What is the difference between Danziten and Imkeldi?

Danziten contains Nilotinib Tartrate, while Imkeldi contains Imatinib Mesylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.